IN2012DN01983A - - Google Patents

Download PDF

Info

Publication number
IN2012DN01983A
IN2012DN01983A IN1983DEN2012A IN2012DN01983A IN 2012DN01983 A IN2012DN01983 A IN 2012DN01983A IN 1983DEN2012 A IN1983DEN2012 A IN 1983DEN2012A IN 2012DN01983 A IN2012DN01983 A IN 2012DN01983A
Authority
IN
India
Prior art keywords
pdgfrp
csf1r
epha2
vegfr2
kit
Prior art date
Application number
Other languages
English (en)
Inventor
Jiang Shan
Xing Xinglong
Wang Qishan
Kong Ren
Original Assignee
Ascepion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascepion Pharmaceuticals Inc filed Critical Ascepion Pharmaceuticals Inc
Publication of IN2012DN01983A publication Critical patent/IN2012DN01983A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IN1983DEN2012 2009-08-24 2010-08-20 IN2012DN01983A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23627409P 2009-08-24 2009-08-24
PCT/CN2010/076199 WO2011023081A1 (en) 2009-08-24 2010-08-20 5,6-bicyclic heteroaryl-containing urea compounds as kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN01983A true IN2012DN01983A (enExample) 2015-07-24

Family

ID=43627250

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1983DEN2012 IN2012DN01983A (enExample) 2009-08-24 2010-08-20

Country Status (20)

Country Link
US (1) US8648086B2 (enExample)
EP (1) EP2470533A4 (enExample)
JP (1) JP2013502444A (enExample)
KR (1) KR20120089459A (enExample)
CN (1) CN102066372B (enExample)
AU (1) AU2010289143A1 (enExample)
BR (1) BR112012003462A2 (enExample)
CA (1) CA2769151A1 (enExample)
CO (1) CO6491087A2 (enExample)
EA (1) EA201290073A1 (enExample)
EC (1) ECSP12011691A (enExample)
IL (1) IL218114A0 (enExample)
IN (1) IN2012DN01983A (enExample)
MA (1) MA33559B1 (enExample)
MX (1) MX2012002317A (enExample)
PH (1) PH12012500366A1 (enExample)
SG (1) SG178092A1 (enExample)
TN (1) TN2012000042A1 (enExample)
WO (1) WO2011023081A1 (enExample)
ZA (1) ZA201200890B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
CA2752421C (en) 2009-03-21 2013-08-06 Ning Xi Amino ester derivatives, salts thereof and methods of use
US20130165475A1 (en) * 2010-09-01 2013-06-27 Ascepion Pharmaceuticals, Inc. Deuterium-enriched heterocyclic compounds as kinase inhibitors
US8580762B2 (en) * 2010-12-03 2013-11-12 Epizyme, Inc. Substituted purine and 7-deazapurine compounds
CN102408426B (zh) * 2011-09-14 2013-07-10 湖南有色凯铂生物药业有限公司 取代的芳香脲类化合物及其作为抗癌药物的应用
FR2985257B1 (fr) * 2011-12-28 2014-02-14 Sanofi Sa Composes dimeres agonistes des recepteurs des fgfs (fgfrs), leur procede de preparation et leur application en therapeutique
CN103420895A (zh) * 2012-05-18 2013-12-04 苏州爱斯鹏药物研发有限责任公司 一种4-氨基吲哚的制备方法
WO2014026198A1 (en) 2012-08-10 2014-02-13 Epizyme, Inc. Inhibitors of protein methyltransferase dot1l and methods of use thereof
CA2883781A1 (en) 2012-09-06 2014-03-13 Epizyme, Inc. Method of treating leukemia
CA2903303A1 (en) 2013-03-15 2014-09-25 Epizyme, Inc. Methods of synthesizing substituted purine compounds
CN103613580B (zh) * 2013-09-03 2016-02-10 遵义医学院 用于抗肿瘤药物的3-羟基吲哚-2-酮类化合物或其药学上能够接受的盐
CN106279154A (zh) * 2016-08-02 2017-01-04 叶芳 一种7‑氮杂吲哚‑3‑甲醛的制备方法
CN108191874B (zh) * 2018-01-16 2019-11-29 成都施贝康生物医药科技有限公司 一种C-Kit抑制剂及其应用
JP7090958B2 (ja) * 2018-06-01 2022-06-27 アドレイ・ノーティ・バイオファーマ・カンパニー・リミテッド 高活性ｃｓｆ１ｒ阻害薬化合物
JP2021534101A (ja) 2018-08-09 2021-12-09 ヴェルソー セラピューティクス， インコーポレイテッド Ｃｃｒ２及びｃｓｆ１ｒを標的とするためのオリゴヌクレオチド組成物ならびにその使用
WO2022123319A1 (en) * 2020-12-11 2022-06-16 Ildong Pharmaceutical Co., Ltd. Biased agonists of opioid receptors
CR20230576A (es) 2021-06-14 2024-04-05 Scorpion Therapeutics Inc Derivados de la urea que pueden ser utilizados para tratar el cáncer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
GB9412719D0 (en) 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
HUP0001943A3 (en) 1997-01-23 2002-12-28 Smithkline Beecham Corp Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them
DE50008597D1 (de) * 1999-03-08 2004-12-16 Bayer Healthcare Ag Thiazolylharnstoff-derivate und ihre verwendung als antivirale mittel
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6525067B1 (en) * 1999-11-23 2003-02-25 Pfizer Inc Substituted heterocyclic derivatives
US20030158188A1 (en) 2002-02-20 2003-08-21 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CN100497302C (zh) * 2002-09-05 2009-06-10 神经研究公司 二芳基脲衍生物和它们作为氯通道阻滞剂的用途
GB0226724D0 (en) 2002-11-15 2002-12-24 Merck Sharp & Dohme Therapeutic agents
UA80171C2 (en) 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
GB0322016D0 (en) 2003-09-19 2003-10-22 Merck Sharp & Dohme New compounds
MXPA06005578A (es) * 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
WO2005073224A2 (en) * 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
EP1756108A2 (en) 2004-04-02 2007-02-28 Vertex Pharmaceuticals Incorporated Azaindoles useful as inhibitors of rock and other protein kinases
US20060058339A1 (en) 2004-06-17 2006-03-16 Ibrahim Prabha N Compounds modulating c-kit activity and uses therefor
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
AU2005316972B2 (en) 2004-11-24 2011-11-10 Abbvie Inc. Chromanylurea compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor and uses thereof
AR054416A1 (es) 2004-12-22 2007-06-27 Incyte Corp Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
NZ556433A (en) * 2005-01-14 2010-10-29 Cgi Pharmaceuticals Inc 1, 3-diaryl substituted ureas as modulators of kinase activity
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
US7777040B2 (en) 2005-05-03 2010-08-17 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
MX2007014377A (es) 2005-05-17 2008-02-06 Plexxikon Inc Inhibidores de proteina cinasa de derivados de pirrol (2,3-b) piridina.
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
FR2889526B1 (fr) 2005-08-04 2012-02-17 Aventis Pharma Sa 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation
JP5072595B2 (ja) * 2005-08-05 2012-11-14 中外製薬株式会社 マルチキナーゼ阻害剤
JP2007099642A (ja) * 2005-09-30 2007-04-19 Tsumura & Co 含窒素複素環化合物、その製造方法およびそれを用いた医薬組成物
RU2008120850A (ru) * 2005-10-28 2009-12-10 Айрм Ллк (Bm) Соединения и композиции в качестве ингибиторов протеинкиназ
AU2006306146A1 (en) 2005-10-28 2007-05-03 Abbott Laboratories Indazole derivatives that inhibit TRPV1 receptor
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
WO2007090141A2 (en) 2006-02-01 2007-08-09 Smithkline Beecham Corporation Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
CN101058561B (zh) 2006-04-19 2011-01-26 苏州爱斯鹏药物研发有限责任公司 用于抑制蛋白激酶的二苯脲衍生物及其组合物和用途
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
PE20081581A1 (es) 2006-12-21 2008-11-12 Plexxikon Inc COMPUESTOS PIRROLO[2,3-b]PIRIDINAS COMO MODULADORES DE QUINASA
WO2008079909A1 (en) 2006-12-21 2008-07-03 Plexxikon, Inc. Pyrrolo [2,3-b] pyridines as kinase modulators
CN101636397B (zh) * 2007-04-13 2012-06-13 中国人民解放军军事医学科学院毒物药物研究所 脲类化合物、其制备方法及其医药用途

Also Published As

Publication number Publication date
CN102066372B (zh) 2014-09-17
EP2470533A1 (en) 2012-07-04
MX2012002317A (es) 2012-06-25
EP2470533A4 (en) 2013-01-23
EA201290073A1 (ru) 2013-01-30
IL218114A0 (en) 2012-04-30
CN102066372A (zh) 2011-05-18
US8648086B2 (en) 2014-02-11
TN2012000042A1 (en) 2013-09-19
ZA201200890B (en) 2012-10-31
CA2769151A1 (en) 2011-03-03
SG178092A1 (en) 2012-03-29
WO2011023081A1 (en) 2011-03-03
JP2013502444A (ja) 2013-01-24
BR112012003462A2 (pt) 2016-02-23
AU2010289143A1 (en) 2012-02-16
KR20120089459A (ko) 2012-08-10
PH12012500366A1 (en) 2012-10-22
CO6491087A2 (es) 2012-07-31
ECSP12011691A (es) 2012-04-30
MA33559B1 (fr) 2012-09-01
US20120122895A1 (en) 2012-05-17

Similar Documents

Publication Publication Date Title
IN2012DN01983A (enExample)
MX2022002581A (es) Compuestos de benzimidazol como inhibidores de c-kit.
PH12013501754A1 (en) Triazolopyridine compounds as pim kinase inhibitors
PH12014502573A1 (en) Substituted pyrrolidines as factor xia inhibitors for the treatment thromboembolic diseases
MX355632B (es) Inhibidores de la trayectoria de señalización notch y uso de los mismos en el tratamiento de cánceres.
MX367897B (es) Derivados de piridazinona macrociclicos.
TN2011000673A1 (en) Bace inhibitors
MX2015009270A (es) Pirazoles sustituidos en posicion 3 y uso de los mismos como inhibidores de la cinasa cremallera de leucinas dual (dlk).
NZ716392A (en) Fused tricyclic urea compounds as raf kinase and/or raf kinase dimer inhibitors
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX348451B (es) Derivados de n-[(1h-pirazol-1-il)aril]-1h-indol o 1h-indazol-3-carboxamida, su preparación y su uso como antagonistas p2y12.
MX2015001720A (es) Hetero-azepinonas sustituidas.
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
MX341456B (es) Amino-quinolinas como inhibidores de cinasa.
MX2015007097A (es) Nuevas fenil-piridinas/pirazinas bi-anulares para el tratamiento de cancer.
UA112795C2 (uk) Біциклічні піразинонові похідні
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
PH12016500347A1 (en) Triazolopyridine compounds, compositions and methods of use thereof
PH12014501534A1 (en) Inhibitors of iap
EA201170447A1 (ru) Производные изохинолинона в качестве антагонистов nk3
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201400214A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
EA201400215A1 (ru) Антраниламидные соединения и их применение в качестве пестицидов
MX2010010000A (es) Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
NZ630436A (en) Novel compounds as diacylglycerol acyltransferase inhibitors